Huntington National Bank Has $73,000 Position in Halozyme Therapeutics, Inc. $HALO

Huntington National Bank cut its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 42.8% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,407 shares of the biopharmaceutical company’s stock after selling 1,053 shares during the quarter. Huntington National Bank’s holdings in Halozyme Therapeutics were worth $73,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the company. Wealth Preservation Advisors LLC acquired a new position in shares of Halozyme Therapeutics in the first quarter valued at about $32,000. SVB Wealth LLC acquired a new position in shares of Halozyme Therapeutics during the 1st quarter worth approximately $33,000. Brooklyn Investment Group grew its position in shares of Halozyme Therapeutics by 1,558.1% during the 1st quarter. Brooklyn Investment Group now owns 713 shares of the biopharmaceutical company’s stock worth $45,000 after purchasing an additional 670 shares in the last quarter. CWM LLC increased its holdings in shares of Halozyme Therapeutics by 46.3% during the first quarter. CWM LLC now owns 1,383 shares of the biopharmaceutical company’s stock worth $88,000 after purchasing an additional 438 shares during the period. Finally, Harvest Fund Management Co. Ltd acquired a new stake in shares of Halozyme Therapeutics in the first quarter valued at approximately $89,000. Institutional investors own 97.79% of the company’s stock.

Insider Activity at Halozyme Therapeutics

In other news, CEO Helen Torley sold 20,000 shares of Halozyme Therapeutics stock in a transaction dated Friday, October 3rd. The stock was sold at an average price of $69.03, for a total transaction of $1,380,600.00. Following the sale, the chief executive officer directly owned 733,719 shares of the company’s stock, valued at approximately $50,648,622.57. This trade represents a 2.65% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Bernadette Connaughton sold 2,000 shares of the company’s stock in a transaction that occurred on Wednesday, October 1st. The shares were sold at an average price of $75.24, for a total value of $150,480.00. Following the completion of the transaction, the director directly owned 44,952 shares of the company’s stock, valued at $3,382,188.48. This represents a 4.26% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 108,227 shares of company stock valued at $7,779,595 in the last 90 days. 2.40% of the stock is owned by corporate insiders.

Halozyme Therapeutics Trading Down 0.2%

Shares of Halozyme Therapeutics stock opened at $68.24 on Friday. The firm has a market capitalization of $8.02 billion, a PE ratio of 15.62, a price-to-earnings-growth ratio of 0.35 and a beta of 1.18. The company has a current ratio of 8.36, a quick ratio of 7.01 and a debt-to-equity ratio of 4.54. The firm’s 50 day moving average is $70.66 and its 200 day moving average is $62.86. Halozyme Therapeutics, Inc. has a 1 year low of $42.01 and a 1 year high of $79.50.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings data on Monday, November 3rd. The biopharmaceutical company reported $1.72 EPS for the quarter, beating the consensus estimate of $1.63 by $0.09. The business had revenue of $354.26 million during the quarter, compared to the consensus estimate of $339.18 million. Halozyme Therapeutics had a net margin of 47.28% and a return on equity of 150.85%. The firm’s revenue was up 22.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.27 EPS. Equities research analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on HALO shares. Weiss Ratings downgraded Halozyme Therapeutics from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Saturday, October 25th. Leerink Partnrs raised Halozyme Therapeutics from a “strong sell” rating to a “hold” rating in a report on Tuesday, October 14th. Zacks Research cut Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, October 6th. Citizens Jmp upped their price objective on shares of Halozyme Therapeutics from $91.00 to $92.00 and gave the stock a “market outperform” rating in a research report on Tuesday, November 4th. Finally, Leerink Partners upgraded shares of Halozyme Therapeutics from an “underperform” rating to a “market perform” rating and set a $70.00 price objective on the stock in a research note on Tuesday, October 14th. Six investment analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Halozyme Therapeutics currently has an average rating of “Hold” and an average target price of $75.00.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.